Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-T in Advanced Solid Tumors with KRAS Mutations
NCT07342738Phase 1Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Shenzhen University General Hospital TCR-T cells in solid tumor, sponsored by Sun Yat-sen University. Primary endpoints: Adverse Events at 1 year and Serious Adverse Events at 1 year. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Shenzhen University General Hospital TCR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07342738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342738.